ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
역형성 성상세포종 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년 연평균 복합 성장률(CAGR)은 6.8%를 나타내 6억 달러로 성장할 전망입니다. 예측 기간의 성장은 연구개발 활동 증가, 맞춤형 의료에 대한 수요 증가, 투자 증가, 질병에 대한 인식 증가, 스트레스와 우울증 증가 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 신경외과 수술의 진보, 방사선치료의 진보, 임상검사와 연구, 원격의료와 원격 모니터링 기술의 채용, 화상진단의 진보, 생명공학과 의약품 개발 등이 있습니다.
향후 5년간의 성장률 6.8%라고 하는 예측은 이 시장의 전회 예측으로부터 0.3%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 이스라엘과 이탈리아에서 개발된 테모졸로미드 캡슐 및 종양 치료용 필드 장치의 가격을 상승시켜 신경 교종 치료 지연과 신경 종양과 비용 상승을 초래하여 미국 신경 종양학을 저해할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 되는 것으로 예측됩니다.
역형성 성상세포종 시장은 원발성 악성 뇌종양과 비악성 뇌종양 모두의 발달이 증가하고 있기 때문에 성장이 예상됩니다. 뇌종양은 뇌 내의 비정상 증식이며, 암성(악성)으로 침윤성 밑에서는 비암성(양성)으로 비침윤성의 것으로 분류되어, 그 악성도나 퍼질 가능성은 다양합니다. 역형성 성상세포종 치료는 뇌 기능을 유지하면서 종양과 그 주변 조직을 제거합니다. 예를 들어 미국에 본사를 둔 비영리 단체인 미국 임상종양학회(ASCO)의 보고에 따르면 2023년 3월 미국에서 원발성 뇌종양과 척수종양 진단을 받은 성인은 약 2만 4,810명으로 남성이 1만 4,280명, 여성이 1만 530명이었습니다. 그 결과, 원발성 악성뇌종양과 비악성뇌종양의 이환율의 상승이, 향후의 역형성 성상세포종 시장 성장을 견인하는 요인이 될 것으로 예상되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 역형성 성상세포종 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 역형성 성상세포종 시장 : 성장률 분석
세계의 역형성 성상세포종 시장 실적 : 규모와 성장(2019-2024년)
세계의 역형성 성상세포종 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 역형성 성상세포종 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 역형성 성상세포종 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
1등급
2등급
3등급
4등급
세계의 역형성 성상세포종 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
수술
화학요법
방사선 치료
세계의 역형성 성상세포종 시장 : 치료 단계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
등록 전 단계
임상 시험 단계
세계의 역형성 성상세포종 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 및 클리닉
소매 약국
온라인 약국
세계의 역형성 성상세포종 시장 : 1등급 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
모세포성 성상세포종
세계의 역형성 성상세포종 시장 : 2등급 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
확산성 성상세포종
올리고도교종
세계의 역형성 성상세포종 시장 : 3등급 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
역형성 성상세포종
역형성 올리고도교종
세계의 역형성 성상세포종 시장 : 4등급 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
다형성 교모세포종(GBM)
원발성 교모세포종
이차성 교모세포종
제7장 지역별/국가별 분석
세계의 역형성 성상세포종 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 역형성 성상세포종 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
역형성 성상세포종 시장 : 경쟁 구도
역형성 성상세포종 시장 : 기업 프로파일
Pfizer Inc.
Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Amgen Inc.
제31장 기타 주요 기업 및 혁신 기업
Teva Pharmaceutical Industries Ltd.
Mylan NV
Eisai Co. Ltd
Boehringer Ingelheim International GmbH
Perrigo Company Plc
Ipsen SA
Genentech Inc
Cipla Limited
Novocure Ltd.
Celon Laboratories Limited
Avid Bioservices Inc.
EirGen Pharma Ltd.
Monteris Medical Corporation
GLS Pharma Pvt. Ltd.
Tocagen Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
역형성 성상세포종 시장(2029년) : 새로운 기회를 제공하는 국가
역형성 성상세포종 시장(2029년) : 새로운 기회를 제공하는 부문
역형성 성상세포종 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Anaplastic astrocytoma is a rare and malignant brain tumor that originates from astrocytes, which are the supportive cells in the nervous system. This condition can lead to neurological symptoms such as headaches, seizures, behavioral changes, and motor deficits, and is typically managed through a combination of surgical procedures, radiation therapy, and chemotherapy.
Anaplastic astrocytoma is categorized into four main grades such as Grade I, Grade II, Grade III, and Grade IV. Grade I anaplastic astrocytoma tumors are the least aggressive and considered benign. They are typically treated with surgical excision, routine monitoring, and follow-up procedures. Treatment options for anaplastic astrocytoma also include surgery, chemotherapy, and radiation, which are further classified into pre-registration and clinical trial phases. These treatments are administered by medical facilities such as hospitals and clinics, and the medications can be obtained from retail pharmacies and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The anaplastic astrocytoma market research report is one of a series of new reports from The Business Research Company that provides anaplastic astrocytoma market statistics, including anaplastic astrocytoma industry global market size, regional shares, competitors with an anaplastic astrocytoma market share, detailed anaplastic astrocytoma market segments, market trends and opportunities and any further data you may need to thrive in the anaplastic astrocytoma industry. This anaplastic astrocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anaplastic astrocytoma market size has grown strongly in recent years. It will grow from $0.44 billion in 2024 to $0.46 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to growing adoption of targeted therapies, patient advocacy and awareness, clinical trial expansion, healthcare policy and funding, government initiatives.
The anaplastic astrocytoma market size is expected to see strong growth in the next few years. It will grow to $0.6 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing research and development activities, growing demand for personalized medicine, growing investments, increasing awareness of the disease, increasing stress and depression. Major trends in the forecast period include advancements in neurosurgery, radiation therapy advancements, clinical trials and research, adoption of telemedicine and remote monitoring technologies, advancements in imaging, biotechnology and drug development.
The forecast of 6.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. neuro-oncology by inflating prices of temozolomide capsules and tumor-treating field devices developed in Israel and Italy, resulting in delayed glioma treatment and higher neuro-oncology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anaplastic astrocytoma market is anticipated to experience growth due to the increasing occurrence of both primary malignant and non-malignant brain tumors. Brain tumors are abnormal growths within the brain that can be categorized as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying levels of aggressiveness and potential to spread. Anaplastic astrocytoma treatment involves the removal of the tumor and surrounding affected tissue while preserving brain function. For instance, as reported by the American Society of Clinical Oncology (ASCO), a non-profit organization based in the United States, it is estimated that around 24,810 adults in the U.S. will receive diagnoses of primary cancerous brain and spinal cord tumors in March 2023, with 14,280 cases in men and 10,530 in women. Consequently, the rising incidence of primary malignant and non-malignant brain tumors is poised to be a driving factor for the growth of the anaplastic astrocytoma market in the future.
The anticipated growth in the anaplastic astrocytoma market is expected to be driven by government funding for brain cancer research. Government funding involves financial support provided by government entities at various levels (federal, state, or local) to support organizations, initiatives, projects, programs, or individuals. Numerous government authorities are actively funding research related to brain cancer treatments, including anaplastic astrocytoma. For example, in June 2023, the Australian Department of Health and Aged Care initiated The Australian Brain Cancer Mission, allocating $136.66 million to support brain cancer research. The mission aims to double survival rates and enhance the quality of life for brain cancer patients, including those with anaplastic astrocytoma. As a result, government funding for brain cancer research is a key driver for the anaplastic astrocytoma market.
Prominent companies in the anaplastic astrocytoma market are actively engaged in pioneering novel treatment options with the aim of enhancing effectiveness, reducing side effects, and ultimately improving patient outcomes. For example, in June 2022, the U.S. Food and Drug Administration, a federal agency based in the United States, granted accelerated approval for an innovative treatment combination featuring the oral medications dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors characterized by the BRAF V600E mutation. This approval applies to both adult and pediatric patients with high- and low-grade gliomas that have shown progression following prior treatments. The BRAF V600E mutation is prevalent in various types of gliomas, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas. The decision to grant approval was based on clinical trials of the Tafinlar-Mekinist combination therapy, which demonstrated tumor shrinkage benefits for both adult and pediatric glioma patients. High-grade glioma patients exhibited a 33% response rate, low-grade glioma patients showed a 50% response rate, and pediatric glioma patients demonstrated a 25% response rate.
Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma's Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.
North America was the largest region in the anaplastic astrocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic astrocytoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anaplastic astrocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anaplastic astrocytoma market consists of revenues earned by entities by providing targeted therapies, genetic testing and biomarker analysis, clinical trials and healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The anaplastic astrocytoma market also includes sales of surgical equipment, imaging devices and radiation therapy equipment that are used in providing anaplastic astrocytoma treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Anaplastic Astrocytoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anaplastic astrocytoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for anaplastic astrocytoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anaplastic astrocytoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Disease Type: Grade I; Grade II; Grade III; Grade IV
2) By Treatment Type: Surgery; Chemotherapy; Radiation
3) By Treatment Phase: Pre-Registration Phase; Clinical Trial Phase
4) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Grade I: Pilocytic Astrocytoma
2) By Grade II: Diffuse Astrocytoma; Oligodendroglioma
3) By Grade III: Anaplastic Astrocytoma; Anaplastic Oligodendroglioma
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Anaplastic Astrocytoma Market Characteristics
3. Anaplastic Astrocytoma Market Trends And Strategies
4. Anaplastic Astrocytoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Anaplastic Astrocytoma Growth Analysis And Strategic Analysis Framework
5.1. Global Anaplastic Astrocytoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anaplastic Astrocytoma Market Growth Rate Analysis
5.4. Global Anaplastic Astrocytoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anaplastic Astrocytoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anaplastic Astrocytoma Total Addressable Market (TAM)
6. Anaplastic Astrocytoma Market Segmentation
6.1. Global Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Grade I
Grade II
Grade III
Grade IV
6.2. Global Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Chemotherapy
Radiation
6.3. Global Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pre-Registration Phase
Clinical Trial Phase
6.4. Global Anaplastic Astrocytoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Retail Pharmacy
Online Pharmacy
6.5. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pilocytic Astrocytoma
6.6. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diffuse Astrocytoma
Oligodendroglioma
6.7. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
6.8. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glioblastoma Multiforme (GBM)
Primary Glioblastoma
Secondary Glioblastoma
7. Anaplastic Astrocytoma Market Regional And Country Analysis
7.1. Global Anaplastic Astrocytoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anaplastic Astrocytoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
